**U. S. Department of Justice**
Drug Enforcement Administration
8701 Morrissette Drive
Springfield, Virginia 22152

*www.dea.gov*

Kathryn L. Tucker, Esq.
Emerge Law Group
621 S.W. Morrison Street
Portland, Oregon 97205
kathryn@emergelawgroup.com

Dear Kathryn Tucker:

This is in response to your letter dated February 10, 2022, to the Drug Enforcement Administration (DEA) regarding the Right to Try Act (RTT), 21 U.S.C. 360bbb-0a, and your client, Advanced Integrative Medical Science Institute and its co-director, Dr. Sunil Aggarwal, M.D. In your correspondence, you again inquired about the use of psilocybin, a schedule I controlled substance, for "therapeutic use" for terminally ill patients suffering anxiety and/or depression, as well as "immunity from prosecution" for such use under the Controlled Substances Act. This latest request effectively restates the grounds that you previously submitted to DEA, to which DEA responded via letter on February 12, 2021 (attached). Accordingly, DEA considers your latest correspondence as a request for reconsideration of the agency's letter to you dated February 12, 2021. DEA finds no basis for reconsideration of its February 12, 2021 letter because the legal and factual considerations remain unchanged.

Nonetheless, as DEA previously indicated, the agency welcomes applications for registration by practitioners seeking to conduct bona fide research with schedule I controlled substances, including psilocybin.

I trust that this letter adequately addresses your inquiry. For additional information regarding the DEA Diversion Control Division, please visit www.DEAdiversion.usdoj.gov. If you have any additional questions on this issue, please contact the Diversion Control Division Policy Section at (571) 362-3260.

Sincerely,

THOMAS PREVOZNIK
Digitally signed by THOMAS PREVOZNIK
Date: 2022.06.28 09:47:18 -04'00'

Thomas W. Prevoznik
Deputy Assistant Administrator
Diversion Control Division

Enclosure